Cardiology

Evolocumab significantly reduces risk of cardiovascular events

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the risk of cardiovascular events ...

Oncology & Cancer

High CVD risk in patients with head, neck squamous cell cancer

(HealthDay)—Twenty-three percent of patients with head and neck squamous cell carcinoma (HNSCC) have cardiovascular disease (CVD) at diagnosis, and 24 percent have uncontrolled blood pressure, according to research published ...

page 6 from 14